ArticleChemical science2026
Pushing the boundaries of BODIPY chemistry: 2-(dimethylamino)methyl BODIPYs as enablers of diversification with nucleophiles.
Article in Chemical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The BODIPY family of organic dyes has emerged as a versatile platform in photonic materials science, driven by their outstanding photophysical properties and the synthetic flexibility of BODIPY chemistry. Post-functionalization strategies have been pivotal in expanding BODIPY's application scope. However, current methodologies for rapid diversification with nucleophiles suffer from key limitations, including the use of unstable intermediates, limited substrate scope, and reliance on hazardous or costly reagents. In this work, we introduce 2-(dimethylamino)methyl BODIPYs as novel, stable, and easily accessible electrophilic intermediates that enable efficient BODIPY diversification with a broad range of neutral protic nucleophiles
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.